SCHEDULE: Bank of America Discloses 7% Stake in CytomX Therapeutics

Bank of America Corporation has reported a beneficial ownership of 7.0% in CytomX Therapeutics, Inc., holding over 15.1 million shares.

Summary

• Bank of America Corporation, through its subsidiaries, now beneficially owns 15,134,689 shares of CytomX Therapeutics, Inc. common stock.
• This represents 7.0% of the class of securities outstanding.
• The filing is made under Schedule 13G, indicating passive investment.
• The reporting entities include BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and Merrill Lynch Pierce Fenner & Smith, Inc.
• The beneficial ownership calculation is based on 217,702,919 outstanding shares as of April 30, 2026, as disclosed in CytomX's Form 10-Q filed on May 7, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• Bank of America's significant stake suggests confidence or strategic interest in CytomX Therapeutics.
• The passive nature of the filing (Schedule 13G) implies no intent to control or influence the company's management.

Negatives

• No new financial performance data or strategic updates are provided in this filing.
• The filing does not offer insights into CytomX's operational performance or future prospects.

Risks

• The significant stake held by a large financial institution could lead to future strategic shifts or influence if their investment thesis changes.
• Market perception of Bank of America's investment could fluctuate based on broader market conditions affecting biotechnology stocks.

Future Outlook

This filing does not contain forward-looking statements or guidance from CytomX Therapeutics. It solely reports on the beneficial ownership of Bank of America Corporation.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant institutional investment, even if passive, in a biotechnology company like CytomX Therapeutics can be a signal of perceived value or future potential within the sector, though this filing itself provides no direct insight into CytomX's pipeline or performance.

Stakeholder Impact

• Shareholders: May view Bank of America's stake as a positive indicator of institutional interest, potentially influencing market perception.
• Creditors: No direct impact as this is a passive investment disclosure.
• Employees: No direct impact from this filing.
• Suppliers: No direct impact from this filing.

Next Steps

• Bank of America will continue to hold its shares in CytomX Therapeutics, subject to its investment strategy.
• CytomX Therapeutics will continue its operations and disclosures as per its regular reporting schedule.

Key Dates

Keywords

CytomX Therapeutics, Bank of America, Schedule 13G, Beneficial Ownership, Biotechnology, Investment, Securities